Regulus raises $100M; Cancer company files to go public

Plus, news about RF Ac­qui­si­tion Corp II, Skye Bio­science, Cog­ni­tion Ther­a­peu­tics, Siol­ta Ther­a­peu­tics and Tier­ra Bio­sciences:

Reg­u­lus Ther­a­peu­tics’ PhI da­ta and $100M raise: The com­pa­ny’s stock $RGLS jumped about 93% on Tues­day morn­ing af­ter it an­nounced pos­i­tive topline da­ta for its ex­per­i­men­tal treat­ment for au­to­so­mal dom­i­nant poly­cys­tic kid­ney dis­ease. The sec­ond co­hort in the Phase Ib tri­al showed RGLS8429 was well tol­er­at­ed. The com­pa­ny al­so an­nounced a $100 mil­lion pri­vate place­ment led by Leerink Part­ners. — An­na Brown

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.